Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).

ABSTRACT:

SUBMITTER: Neubauer A 

PROVIDER: S-EPMC7298698 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature